First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers

A first-in-human phase I trial of Vvax001, an alphavirus-based therapeutic cancer vaccine against human papillomavirus (HPV)-induced cancers was performed assessing immunological activity, safety, and tolerability. Vvax001 consists of replication-incompetent Semliki Forest virus replicon particles e...

Descripción completa

Detalles Bibliográficos
Autores principales: Komdeur, Fenne L., Singh, Amrita, van de Wall, Stephanie, Meulenberg, Janneke J.M., Boerma, Annemarie, Hoogeboom, Baukje Nynke, Paijens, Sterre T., Oyarce, Cesar, de Bruyn, Marco, Schuuring, Ed, Regts, Joke, Marra, Ruben, Werner, Naomi, Sluis, Jessica, van der Zee, Ate G.J., Wilschut, Jan C., Allersma, Derk P., van Zanten, Coba J., Kosterink, Jos G.W., Jorritsma-Smit, Annelies, Yigit, Refika, Nijman, Hans W., Daemen, Toos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854293/
https://www.ncbi.nlm.nih.gov/pubmed/33160073
http://dx.doi.org/10.1016/j.ymthe.2020.11.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7854293/
https://www.ncbi.nlm.nih.gov/pubmed/33160073
http://dx.doi.org/10.1016/j.ymthe.2020.11.002

Ejemplares similares